
Bundhun et al. BMC Cardiovascular Disorders (2015) 15:118 DOI 10.1186/s12872-015-0114-1









Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials

Pravesh Kumar Bundhun, Tao Qin and Meng-Hua Chen*

Abstract

Background: Since antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients is very important after intracoronary stenting, and because the most commonly used therapies have been the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel and the triple antiplatelet therapy (TAPT) consisting of aspirin, clopidogrel and cilostazol, we aim to compare the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in T2DM patients.

Methods: Systematic literature search was done from the databases of PubMed, Cochrane, Embase, China National Knowledge Infrastructure (CNKI) and WanFang. Randomized controlled trials (RCTs) comparing the effectiveness and safety between triple therapy and dual therapy in T2DM patients after coronary stents placement were included. Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9–12 months period, as well as platelet activities.

Results: Four studies including 1005 patients reporting the adverse clinical outcomes and six studies including 519 patients reporting the platelet activities, with a total of 1524 patients have been analyzed in this meta-analysis. The pooling analysis shows that TAPT has significantly decreased the occurrence of MACEs (RR: 0.55; 95 % Cl: 0.36–0.86, P = 0.009), TLR (RR 0.41; 95 % Cl: 0.21–0.80, P = 0.008), TVR (RR 0.55; 95 % Cl: 0.34–0.88, P = 0.01) and the overall incidence of Death/ Myocardial Infarction (MI)/TVR (RR 0.54; 95 % Cl: 0.31–0.94, P = 0.03) during this 9 to 12 months follow up period after stents implantation. Stent thrombosis was almost similar in both groups. Bleeding seemed to favor DAPT but the result was not statistically significant. Platelet aggregation, platelet reactivity index (PRI) and platelet reactivity unit (PRU) were also reduced with Weight Mean Difference (WMD) of (–13.80; 95 % Cl: –17.03 to –10.56, P < 0.00001), (–22.87; 95 % Cl: –23.66 to –22.07, P < 0.00001) and (–44.17; 95 % Cl: –58.56 to –29.77, P < 0.00001) respectively.

Conclusion: Since MACEs have been significantly decreased in the triple group, TAPT appears to be more effective than DAPT in T2DM patients after intracoronary stenting. No significant difference in stent thrombosis and bleeding risks between these 2 groups shows TAPT to be almost as safe as DAPT in these diabetic patients.

Keywords: Antiplatelet therapy, Cilostazol, Type 2 diabetes mellitus, Coronary stents implantation

* Correspondence: cmhnn@sina.com

Institute of Cardiovascular Diseases, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530027, P. R. China



© 2015 Bundhun et al. **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Background

Nowadays percutaneous coronary intervention (PCI) is becoming the preferred invasive procedure in patients suffering from coronary artery disease (CAD) and acute coronary syndrome (ACS) which are chronic macrovascular complications in type 2 diabetes mellitus (T2DM) patients. Several studies have shown that T2DM patients are more exposed to many adverse clinical outcomes such as major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR) and stent thrombosis after intracoronary stenting [1]. Platelet dysfunction is among one of the reasons T2DM patients have an increased risk of atherothrombotic events [2, 3]. In particular, T2DM patients have increased platelet reactivity warranting the use of platelet-inhibiting strategies in order to reduce their ischemic risk after stents implantation. Since cardiovascular disease is the leading cause of morbidity and mortality in patients with T2DM and because the latter usually present with atypical symptoms in these patients, antiplatelet therapies in these high risk patients after coronary stents placement are extremely important. Although currently approved antiplatelet treatment strategies have proven useful in improving outcomes, T2DM patients continue to have a higher risk of adverse cardiovascular events especially after stents implantation. Several antiplatelet therapies have been tried but the most commonly used have been the dual antiplatelet therapy (DAPT) consisting of aspirin and clopidogrel, as mentioned in Emmanouil's study [4], and the triple antiplatelet therapy (TAPT) consisting of aspirin, clopidogrel and cilostazol [5-9]. Studies show that TAPT has been a better option in T2DM patients compared to DAPT [10] but the treatments have not yet been well established systematically. Therefore, by performing a meta-analysis, we sought to evaluate systematically whether TAPT is more effective and safe to use compared to DAPT in T2DM patients after coronary stents implantation.

The abbreviations and acronyms used in this metaanalysis have been represented in Table 1.

 Table 1 Abbreviations and acronyms

Type 2 diabetes mellitus
Percutaneous coronary intervention
Dual antiplatelet therapy
Triple antiplatelet therapy
Target vessel revascularization
Target lumen revascularization
Major adverse cardiac effects
Platelet reactivity index
Weight mean difference

Methods

Eligibility and search strategy

Relevant randomized controlled trials (RCTs) were identified through a computerized literature search from PubMed, Cochrane, Embase/Science Direct, China National Knowledge Infrastructure (CNKI) and WanFang databases using the search terms "Diabetes + Coronary Stents + Dual and/or Triple Anti platelet therapy". Different wordings of the same meanings have also been used such as "PTCA/PCI, DAPT, TAPT, T2DM, coronary angioplasty and anti-platelets". No language restrictions were used. All data were independently extracted by two investigators and then the results were compared, and disagreements were resolved by discussing with a third investigator before December 2014.

Inclusion and exclusion criteria

Studies included in our meta-analysis were trials that: (a) randomly assigned patients for RCTs (b) included T2DM patients (wherever possible, selecting only T2DM patients in studies consisting of both T2DM and non-T2DM or retrieving the number of diabetic patients among other disease conditions such as acute coronary syndrome or long coronary lesion) (c) compared TAPT (aspirin, clopidogrel and cilostazol) with DAPT (aspirin and clopidogrel) (d) reported any of the corresponding endpoints including MACEs, TLR, TVR, stent thrombosis, bleeding and adverse drug reactions as well as platelet aggregation, PRI and PRU.

Exclusion criteria were trials (a) of retrospective nonrandomized studies (b) including only non-diabetic patients (c) including another drug instead of cilostazol in the TAPT group (d) considering only DAPT or TAPT separately without comparison (e) with duplicate reports.

Data extraction and quality assessment

Two authors (P.K.B. and T.Q.) independently reviewed the data and assessed the eligibility and methodological quality of each eligible trial. Information regarding study and patient characteristics, intervention strategies, and the pre-specified clinical outcomes was systematically extracted. Disagreements were discussed between the authors, and if the authors could not reach a consensus, disagreements were resolved by the third author (M.H.C.). The bias risk of trials was assessed with the components recommended by the Cochrane Collaboration, including sequence generation of the allocation, allocation concealment, blinding of participants, personnel, and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. Quality scale was used to assess the trials: (A) true randomization and allocation concealed, and (B) process of randomization not given and concealment of allocation unclear. This approach was recommended by Cochrane Collaboration.

Definitions, outcomes and follow-up

Major adverse cardiac effects: MACEs were defined as death of cardiac or procedure-related origin, MI, and repeat target lesion revascularization after stents implantation. Major adverse cardiovascular and cerebrovascular events (MACCEs) have also been considered together in this section.

Revascularization: included TLR and TVR. Revascularization was clinically indicated if there was >70 % diameter stenosis on angiography or >50 % stenosis together with a positive stress test or ischemic symptoms. TLR was defined as clinically indicated percutaneous or surgical revascularization of the index lesion during follow-up.

Stent thrombosis: which could occur acutely (within 24 h), sub-acutely (within 30 days), or as late as 1 year (late) after stent placement throughout the whole follow up period.

Bleeding: was defined as any hemorrhagic event which could occur with the use of the anti-platelets after stents implantation and included minor, major or minimal bleeding in this study.

Adverse drug reactions: included the adverse effects associated with the use of these anti-platelets. For example, rashes, gastrointestinal troubles, thrombocytopenia, liver dysfunction and finally drug discontinuation due to these adverse effects.

Platelet aggregation: defined as the clumping together of platelets in the blood.

PRI and PRU: dealt with the reactivity and activation of platelets after antiplatelet use.

The follow-up for these adverse clinical outcomes as well as the adverse drug reactions was for a period of 9 months in two studies and 12 months in the other two studies. For the platelet aggregation, PRI and PRU, the follow up period was randomly assumed to be during any given time after stents implantation.

Statistical analysis

Risk ratio (RR) with 95 % confidence interval (CI) was used to express the pooled effect on discontinuous variables. For continuous variables, standard deviation for each group was calculated using the formula

 $s = \sqrt{\frac{1}{N-1}\sum_{i=1}^{N} (x_i - \bar{x})^2}$ and data were evaluated by means

of weighted mean differences (WMDs) and 95 % confidence intervals (CIs). Heterogeneity across the trials was assessed using the Cochrane Q-statistic ($p \leq 0.05$ was considered significant) and I²-statistic. I² describes the percentage of total variation across studies that is due to heterogeneity rather than chance. A value of 0 % indicates no heterogeneity, and larger values indicate increased heterogeneity. If I² was <50 %, fixed effect model was used. However, if I² was >50 %, a random effect model was used

[11]. Publication bias was visually estimated by assessing funnel plots. The pooled analyses were performed with RevMan 5.3.

Results

Selected studies and baseline characteristics

From the initial literature search, 211 items in PubMed, 597 in Embase, 341 in CNKI, 416 in WanFang databases and 19 in the Cochrane database were identified. After an elaborative screening, 15 RCTs satisfied our inclusion criteria studies. However, after eliminating the duplicate studies, 10 RCTs have been finally selected for our meta-analysis.

Among these ten studies, four studies including 1005 patients (487 in the DAPT, 518 in the TAPT group) reported the adverse clinical outcomes in these T2DM patients whereas the remaining six studies with 519 patients (287 in the DAPT group, 232 in the TAPT group) reported the platelet activities. A total of 1524 patients (774 and 750 patients following TAPT and DAPT respectively) fulfilled the inclusion criteria and have been finally included in our meta-analysis. Figure 1 shows the flow of the process for identifying potentially eligible trials and the reasons for exclusion.

Trials included in this meta-analysis with their total number of patients (including DAPT and TAPT) and their corresponding endpoints have been represented in Table 2.

According to Table 2, four studies reported adverse cardiovascular outcomes as their endpoints. The other remaining trials dealt with platelet activities.

Table 3 summarizes the baseline characteristics for each of the included trials. No significant differences have been found in the baseline characteristics between the 2 groups.

Patients in most of the studies used beta-blockers and ACEI/ARB routinely. Moreover, patients in few of the studies also use statins as part of their routine medications. The use of glycoprotein IIb/IIIa was dependent on the physician's decision during the procedure.

For the studies related to platelet activities, such as platelet aggregation, PRI and PRU; the mean has been calculated first as well as the standard deviation. In a few of the studies, since there was a period of crossover adding cilostazol to the DAPT or removing cilostazol from the TAPT after complete washout; the participants have been considered as different individuals before and after the crossover period despite of being the same patients. For example, in Angiolillo's study there were 20 participants. These 20 participants were treated first with DAPT for 2 weeks and then after a washout period, the same 20 participants were treated with TAPT. In such a case, we have considered the number of patients undergoing DAPT to




Table 2 Shows the endpoints reported by each of the included trials

Trials	No of patients (DAPT + TAPT)	Follow up period (month)	Reported endpoints/outcomes
Han 2009 [6]	263	12	MACEs, TVR, and ADR.
Lee 2011 [33]	176	12	MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.
Lee 2008 [5]	400	9	MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.
Lee 2007 [34]	166	9	MACEs, TVR, TLR, ST, D/MI/TVR, BL and ADR.
Yang 2011 [35]	154	-	PRU and PA
Yang 2007 [36]	55	7	PA
Capranzano 2012 [37]	80	1	PRU and PRI
Angiolillo 2008 [38]	40	1	PRI and PA
Angiolillo 2011 [39]	106	1	PRI
Ha 2013 [40]	84	2	PRU and PA

Abbreviations: MACEs major adverse cardiac effects, TVR target vessel revascularization, TLR target lesion revascularization, BL bleeding, ST stent thrombosis, ADR adverse drug reactions, D death, MI myocardial infarction, PA platelet aggregation, PRI platelet reactivity index, PRU platelet reactivity unit

Study/Year	Age (yrs)	Male (%)	Ht (%)	Hc (%)	Cs (%)	Qa
	T/D	T/D	T/D	T/D	T/D	
Lee 2007 [34]	60.9/61.2	64.8/63.6	54.8/55.2	30.0/28.4	37.6/37.2	В
Lee 2008 [5]	61.0/60.7	59.0/57.0	59.5/59.5	30.5/28.5	24.0/31.5	В
Yang 2011 [35]	63.5/63.5	62.3/62.3	55.8/55.8	37.7/37.7	28.6/28.6	В
Yang 2009 [36]	63.4/63.8	40.0/60.0	61.9/57.1	28.6/41.2	14.3/20.6	В
Capranzano 2012 [37]	60.4/60.4	60.2/60.2	91.2/91.2	97.0/97.0	37.1/37.1	В
Angiolillo 2008 [38]	64.0/64.0	60.0/60.0	96.0/96.0	92.0/92.0	24.0/24.0	В
Angiolillo 2011 [39]	60.5/60.5	63.0/63.0	95.0/95.0	100.0/100.0	28.0/28.0	В
Ha 2013 [40]	64.9/62.3	67.7/76.1	71.4/76.1	33.3/42.5	23.8/23.8	В
Lee 2011 [33]	60.9/62.1	70.0/71.5	58.4/64.7	42.4/45.0	30.4/30.1	В
Han 2009 [6]	59.6/60.2	73.8/72.9	57.9/56.1	45.5/45.4	_	В

Table 3 Baseline characteristics of patients from the included studies

Abbreviations:NM not mentioned, Ht hypertension, Hc hypercholesterolemia; Cs current smoker, T triple therapy, D dual therapy

^aQuality scale: A true randomization and allocation concealed; B process of randomization not given and concealment of allocation unclear

be 20 and the number of patients undergoing TAPT to be 20. And finally we have considered the total number of patients to be 40. These values have been used in the results.

All the patients were above 60 years old of age and most of them were males. In three studies, the percentage of patients suffering from hypertension was above 90 % while in the remaining studies, 50–70 % suffered from high blood pressure. Three studies reported a hyperlipidemia level of more than 90 % whereas the amount of participants who were smokers did not exceed 40 %.

The mean Quantitative Angiographic Measurement of the included studies showing the lesion length, stented length, minimal lumen diameter before and after the procedure and the diameter of the stenosis before and after the procedure have been illustrated in Table 4.

There were no differences in angiographic measurements between the 2 groups in those included studies.

Result of the meta-analysis

The pooling analysis shows that TAPT significantly decreased the occurrence of overall MACEs among the 1005 patients reporting this outcome with (RR: 0.55, 95 % CI: 0.36–0.86; P = 0.009), TLR (RR 0.41; 95 % CI: 0.21–0.80; P = 0.008) and TVR (RR 0.55; 95 % CI: 0.34–0.88; P = 0.01) in these T2DM patients after coronary stents implantation. TAPT treatment showed superiority in reducing the overall Death/MI/TVR (RR 0.54; 95 % CI: 0.31–0.94; P = 0.03) compared to DAPT. Stent thrombosis (RR 0.95; 95 % CI: 0.19–4.76, P = 0.95) was similar in both groups and the result for bleeding (RR 0.80; 95 % CI: 0.40–1.59, P = 0.52) was not statistically significant. TAPT showed to be more beneficial in these T2DM patients by significantly reducing the platelet aggregation WMD: (–13.80; 95 % CI: –17.03 to

-10.56, *P* < 0.00001), PRI WMD: (-22.87; 95 % CI: -23.66 to -22.07, *P* < 0.00001) and PRU WMD: (-44.17; 95 % CI: -58.56 to -29.77, *P* < 0.00001) respectively.

Results for the associated adverse effects between these 2 groups were as follow: (RR 2.67; 95 % CI: 1.26– 5.65; P = 0.01) for rashes being higher in the TAPT group; (RR 1.76; 95 % CI: 0.77–4.01; P = 0.18) for gastrointestinal troubles; (RR 0.33; 95 % CI: 0.01–8.13; P = 0.50) for thrombocytopenia; (RR 0.72; 95 % CI: 0.16–3.18; P = 0.67) for hepatic dysfunction; (RR 6.18;

Table 4 Shows the mean Quantitative Angiographic Measurement

 of the included studies^a

Variables (mm)	TAPT group (<i>n</i> = 377)	DAPT group (<i>n</i> = 365)
Reference diameter	2.81	2.79
Lesion length	31.5	31.7
Stented length	37.45	36.05
Minimal lumen diameter in segment before procedure	0.81	0.79
Minimal lumen diameter in segment after procedure	2.25	2.24
Minimal lumen diameter in stent after procedure	2.57	2.58
Stenosis diameter in segment before procedure (%)	70.3	70.4
Stenosis diameter in segment after procedure (%)	17.7	17.2
Stenosis diameter in stent after procedure (%)	8.45	7.57
Acute gain in segment	1.44	1.46
Acute gain in stent	1.76	1.79

^aData from trials Lee 2007 [34], Lee 2008 [5] and Lee 2011 [33] have been included in this table. Quantitative Angiographic Measurement data for study Han 2009 [6] was not available and therefore have been omitted

95 % CI: 0.76–50.20; P = 0.09) for palpitation and (RR 3.56; 95 % CI: 0.76–16.54; P = 0.11) for headache. Moreover, the risk ratio for patients to discontinue TAPT due to these adverse effects was (RR 3.75; 95 % CI: 2.18–6.46; P < 0.00001). The detailed results have been illustrated in Figs. 2, 3 and 4.

The funnel plots assessing publication bias in the included studies have been illustrated in Fig. 5a and b.

For all of the above analyses, sensitivity analyses yielded consistent results. Based on a visual inspection of the funnel plots, there has been no evidence of publication bias for the included studies that assessed all clinical endpoints.

Discussion

Aim and results of this study

The aim of the current study was to perform a comprehensive meta-analysis of several RCTs comparing and analyzing the effectiveness and safety between TAPT (aspirin, clopidogrel and cilostazol) and DAPT (aspirin and clopidogrel) in T2DM patients after coronary stents implantation.

Results from this study including 1005 patients reporting adverse clinical outcomes as their endpoints show that TAPT is more effective than DAPT in several aspects in T2DM patients. TAPT has significantly decreased platelet aggregation, PRI and PRU among the 519 patients analyzed. MACEs, TLR and TVR which are more prominent among diabetic patients, have also decreased significantly with the use of this cilostazol based TAPT. Stent thrombosis was similar in both groups. However, TAPT did not significantly increase the bleeding in these T2DM patients.

Mechanisms of cilostazol in this TAPT

Several reasons are associated with these benefits and effectiveness of this TAPT. First of all, cilostazol has a different mechanism of action compared to aspirin and clopidogrel. It is a phosphodiesterase III (PDE3) inhibitor that plays the role of increasing cyclic adenosine monophosphate within platelets and thus leads to reduced aggregation of platelets [12]. Cilostazol can also inhibit expression of stent-induced P-selectin and the subsequent Mac-1-mediated leukocyte activation that is the trigger of restenosis after PCI [13]. To further explain this mechanism is thought to be the inhibition of neo-intimal proliferation, considered to be a major mechanism of restenosis after PCI caused by smooth muscle cells (SMC) migration, proliferation, and matrix synthesis. SMC migration and proliferation are induced by growth factors released from activated platelets. As an antiplatelet medication, cilostazol controls the induction by platelet-derived growth factors. More importantly, cilostazol is thought to directly inhibit SMC growth. In addition, there is much evidence that Mac-1 is one of the key proteins in the mechanism of restenosis. Studies have demonstrated clinically that PCI induced activation and upregulation of Mac-1 on the surface of neutrophils and that Mac-1 kinetics were linked to angiographic late lumen loss—known as neo-intimal thickening. Cilostazol may inhibit Mac-1—mediated leukocyte activation (act as a Mac-1 blocker) directly or through P-selectin—mediated platelet activation, which may lead to a reduction in the rate of restenosis after coronary stent implantation. This unique property of cilostazol makes it different from all the other anti-platelet agents.


Moreover, since T2DM have platelets hyperactivity, and are usually victims of aspirin and clopidogrel hyporesponsiveness, this adjunctive cilostazol can help to inhibit platelet aggregations and activation which might not be completely possible with the use of DAPT [14]. These mechanisms could be used to explain the better effect of this cilostazol-based TAPT compared to DAPT especially in these T2DM patients who are more at risk of these serious adverse cardiac events after coronary stenting.

TAPT and DAPT in other studies

Similar to our results which showed that TAPT decreased MACEs, TLR as well as TVR, Mohammad's study published in 2010 also indicated that TAPT was more effective after drug eluting stents (DES) placement since it was associated with decreased TLR and MACEs in high risk patients [15]. Another example is Bangalore's meta-analysis consisting of 41 trials conducted in 2014 [16]. This meta-analysis was also in favor of using cilostazol associated TAPT due to a significant reduction in both stent thrombosis and restenosis but, however, his study was not restricted to T2DM patients. Min's study published in 2007 (including 23 % of the population with T2DM using TAPT and 29 % using DAPT) also concluded that the cilostazol based TAPT seemed to be more effective at preventing in-stent neointimal hyperplasia than a dual antiplatelet regimen [17]. Moreover, the results from the DECREASED registry showed that TAPT significantly reduced 12-month risks of stent thrombosis and MI after DES implantation compared with DAPT without any increase risk of bleeding complications [18]. In another meta-analysis, this time conducted by Sakurai, in 2013, TAPT was associated with significantly effective outcomes for TLR and TVR without any increase in MACEs [19]. A study by Kim published in 2011 including almost 30 % T2DM using TAPT, also supports our results showing that compared with high-dose clopidogrel in DAPT, adjunctive cilostazol significantly enhanced platelet inhibition and reduced the rate of high platelet reactivity showing that TAPT is apparently more effective than DAPT [20]. Moreover, the study by Douglas et al. which included 23 % of diabetic patients treated with TAPT and 28 %

	TAPT		DAP			Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	<u>Events</u>	Total	Weight	M-H, Fixed, 95% C	M-H, Fixed, 95% Cl
1.1.1 Target Lesion R	evascular	rization	(TLR)				
Lee2007	2	85	6	81	3.5%	0.32 [0.07, 1.53]	
Lee2008	5	200	14	200	8.0%	0.36 [0.13, 0.97]	
Lee2011	5	92	8	84	4.8%	0.57 [0.19, 1.68]	
Subtotal (95% CI)		377		365	16.3%	0.41 [0.21, 0.80]	\bullet
Total events	12		28				-
Heterogeneity: Chi ² = (P(P=0)		0%			
Test for overall effect: 2	-	•	· · ·	0,0			
1.1.2 Target Vessel R	evascular	ization	(TVR)				
Han2009	11	141	13	122	8.0%	0.73 [0.34, 1.57]	_ _
Lee2007	3	85	6	81	3.5%	0.48 [0.12, 1.84]	
Lee2008	7	200	16	200	9.2%	0.44 [0.18, 1.04]	_
Lee2011	5	92	. 9	84	5.4%	0.51 [0.18, 1.45]	
Subtotal (95% CI)	Ũ	518	Ū	487	26.1%	0.55 [0.34, 0.88]	\bullet
Total events	26		44				
Heterogeneity: Chi ² = (B(P=0)		0%			
Test for overall effect: 2		•		0 /0			
	2.51 (1	- 0.01	,				
1.1.3 Death/MI/TVR							
Lee2007	3	85	6	04	2 E0/	0.48 [0.12, 1.84]	
				81 200	3.5%		_ _
Lee2008	8	200	16	200	9.2%	0.50 [0.22, 1.14]	
Lee2011	7	92 377	10	84 365	6.0%	0.64 [0.25, 1.60]	
Subtotal (95% CI)		311		305	18.7%	0.54 [0.31, 0.94]	
Total events	18		32				
Heterogeneity: Chi ² = ().20, df = 2	2 (P = 0.	91); l² =	0%			
Test for overall effect: 2	Z = 2.16 (F	P = 0.03)				
1.1.4 Stent thrombosi	is						
Lee2007	1	85	1	81	0.6%	0.95 [0.06, 14.98]	
Lee2008	0	200	1	200	0.9%	0.33 [0.01, 8.13]	· · · · · · · · · · · · · · · · · · ·
Lee2011	1	92	0	84	0.3%	2.74 [0.11, 66.40]	
Subtotal (95% CI)		377		365	1.7%	0.95 [0.19, 4.76]	
Total events	2		2				
Heterogeneity: Chi ² = ().84. df = 2	2(P = 0.)	66): ² =	0%			
Test for overall effect:							
1.1.5 Bleeding							
Han2009	4	141	2	122	1.2%	1.73 [0.32, 9.28]	
Lee2007	1	85	1	81	0.6%	0.95 [0.06, 14.98]	
	3	200	3	20	3.1%	0.10 [0.02, 0.46]	
		200					
Lee2008		02	6	0/		1 07 0 27 2 0/1	
Lee2011	7	92 518	6	84 307	3.6%	1.07 [0.37, 3.04]	
Lee2011 Subtotal (95% CI)	7	92 518		84 307	3.6% 8.5%	1.07 [0.37, 3.04] 0.80 [0.40, 1.59]	-
Lee2011 Subtotal (95% CI) Total events	7 15	518	12	307			-
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8	7 15 8.18, df = 3	518 3 (P = 0.	12 04); I² =	307			•
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8	7 15 8.18, df = 3	518 3 (P = 0.	12 04); I² =	307			•
Lee2011 Subtotal (95% Cl) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 2	7 15 8.18, df = 3 Z = 0.64 (F	518 3 (P = 0. P = 0.52	12 04); l² =)	307			•
Lee2011 Subtotal (95% CI) Total events	7 15 8.18, df = 3 Z = 0.64 (F	518 3 (P = 0. P = 0.52	12 04); l² =)	307			
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14	518 3 (P = 0. P = 0.52 ffects (N 141	12 04); I ² =) IACEs) 18	307 63% 122	8.5% 11.1%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2	518 3 (P = 0. P = 0.52 ifects (N 141 85	12 04); I ² =) IACEs) 18 6	307 63% 122 81	8.5% 11.1% 3.5%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 2 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6	518 3 (P = 0. P = 0.52 fects (N 141 85 200	12 04); I ² =) IACEs) 18 6 14	307 63% 122 81 200	8.5% 11.1% 3.5% 8.0%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53) 0.43 (0.17, 1.09)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008 Lee2011	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2	518 3 (P = 0. P = 0.52 ifects (N 141 85 200 92	12 04); I ² =) IACEs) 18 6	307 63% 122 81 200 84	8.5% 11.1% 3.5% 8.0% 6.0%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53) 0.43 (0.17, 1.09) 0.64 (0.25, 1.60)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 2 1.1.6 Major Adverse C Han2009 Lee2007 Lee2007 Lee2008 Lee2011 Subtotal (95% CI)	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7	518 3 (P = 0. P = 0.52 fects (N 141 85 200	12 04); l ² =) IACEs) 18 6 14 10	307 63% 122 81 200	8.5% 11.1% 3.5% 8.0%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53) 0.43 (0.17, 1.09)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 2 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008 Lee2011 Subtotal (95% CI) Total events	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29	518 3 (P = 0. P = 0.52 ffects (N 141 85 200 92 518	12 04); l ² =) 1ACEs) 18 6 14 10 48	307 63% 122 81 200 84 487	8.5% 11.1% 3.5% 8.0% 6.0%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53) 0.43 (0.17, 1.09) 0.64 (0.25, 1.60)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 2 1.1.6 Major Adverse C Han2009 Lee2007 Lee2007 Lee2008 Lee2011 Subtotal (95% CI)	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29 1.20, df = 3	518 3 (P = 0. 5 = 0.52 ffects (N 141 85 200 92 518 3 (P = 0.	12 04); ² =) 1ACEs) 18 6 14 10 48 75); ² =	307 63% 122 81 200 84 487	8.5% 11.1% 3.5% 8.0% 6.0%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53) 0.43 (0.17, 1.09) 0.64 (0.25, 1.60)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008 Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 7	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29 1.20, df = 3	518 3 (P = 0.52) 5 = 0.52 141 85 200 92 518 3 (P = 0.52) 200 92 518 3 (P = 0.52)	12 04); ² =) IACEs) 18 6 14 10 48 75); ² =	307 63% 122 81 200 84 487 0%	8.5% 11.1% 3.5% 8.0% 6.0% 28.6%	0.80 [0.40, 1.59] 0.67 [0.35, 1.30] 0.32 [0.07, 1.53] 0.43 [0.17, 1.09] 0.64 [0.25, 1.60] 0.55 [0.36, 0.86]	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008 Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 7 Total (95% CI)	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29 1.20, df = 3 Z = 2.62 (F	518 3 (P = 0. 5 = 0.52 ffects (N 141 85 200 92 518 3 (P = 0.	12 04); l ² =) 1 ACEs) 18 6 14 10 48 75); l ² = 9)	307 63% 122 81 200 84 487 0%	8.5% 11.1% 3.5% 8.0% 6.0%	0.80 (0.40, 1.59) 0.67 (0.35, 1.30) 0.32 (0.07, 1.53) 0.43 (0.17, 1.09) 0.64 (0.25, 1.60)	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008 Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 7 Total (95% CI) Total events	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29 1.20, df = 3 Z = 2.62 (F 102	518 3 (P = 0. P = 0.52 ifects (N 141 85 200 92 518 3 (P = 0. P = 0.00 2685	12 04); l ² =) 18 6 14 10 48 75); l ² = 9)	307 63% 122 81 200 84 487 0% 2376	8.5% 11.1% 3.5% 8.0% 6.0% 28.6%	0.80 [0.40, 1.59] 0.67 [0.35, 1.30] 0.32 [0.07, 1.53] 0.43 [0.17, 1.09] 0.64 [0.25, 1.60] 0.55 [0.36, 0.86]	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007 Lee2007 Lee2008 Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Total (95% CI) Total events Heterogeneity: Chi ² = 1	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29 1.20, df = 3 Z = 2.62 (F 102 12.90, df =	518 3 (P = 0. P = 0.52 ifects (N 141 85 200 92 518 3 (P = 0. P = 0.00 2685 20 (P =	12 04); I ² = 18 6 14 10 48 75); I ² = 9) 166 0.88); I ²	307 63% 122 81 200 84 487 0% 2376	8.5% 11.1% 3.5% 8.0% 6.0% 28.6%	0.80 [0.40, 1.59] 0.67 [0.35, 1.30] 0.32 [0.07, 1.53] 0.43 [0.17, 1.09] 0.64 [0.25, 1.60] 0.55 [0.36, 0.86]	
Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 8 Test for overall effect: 7 1.1.6 Major Adverse C Han2009 Lee2007 Lee2008 Lee2011 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 1 Test for overall effect: 7 Total (95% CI) Total events	7 15 8.18, df = 3 Z = 0.64 (F Cardiac Ef 14 2 6 7 29 1.20, df = 3 Z = 2.62 (F 102 12.90, df =	518 3 (P = 0. P = 0.52 ifects (N 141 85 200 92 518 3 (P = 0. P = 0.00 2685 20 (P =	12 04); I ² = 18 6 14 10 48 75); I ² = 9) 166 0.88); I ²	307 63% 122 81 200 84 487 0% 2376	8.5% 11.1% 3.5% 8.0% 6.0% 28.6%	0.80 [0.40, 1.59] 0.67 [0.35, 1.30] 0.32 [0.07, 1.53] 0.43 [0.17, 1.09] 0.64 [0.25, 1.60] 0.55 [0.36, 0.86]	• • • • • • • • • • • • • • • • • • •

Fig. 2 Forest plot comparing the adverse clinical outcomes between TAPT and DAPT in T2DM patients after intracoronary stenting. Adverse clinical outcomes have decreased with the use of this TAPT during a follow up period of 9 to 12 months after coronary stenting



treated with DAPT showed that cilostazol-treated patients with oral hypoglycemic medications experienced a highly significant 63 % reduction in the risk of restenosis (P < 0.006) [21]. The study by Jeong et al. demonstrated that among his 30 % T2DM patients using TAPT and 13.3 % using the standard DAPT, the use of TAPT may achieve adequate inhibition of ADP-induced platelet aggregation to suppress the occurrence of major adverse cardiovascular events [22]. Finally, the CIDES trial which dealt with only T2DM patients showed that cilostazol was better than clopidogrel after drug eluting stents implantation in these patients. However, this study did not compare TAPT with DAPT; but instead, compared the clinical outcomes with the use of cilostazol and clopidogrel separately [23]. All of these studies show that TAPT is more effective and could safely be used as it is expected not to cause any increase in bleeding. In other words, apart from being more effective, TAPT is expected to be at least as safe as DAPT in T2DM patients.

However, even if many studies support our results, there are still a few studies whose results were completely different from our study. For example, the multicenter randomized trial conducted by Suh criticized the use of cilostazol as a component of the TAPT after stents implantation. But, the author accepted that his CILON- T trial had a different composition of patients and primary endpoints. The trial did not assess the beneficial role of cilostazol during PCI and included relatively lowrisk patients. The author also precised that DECLARE DIABETES and DECLARE LONG studies which we have used in our meta-analysis had enrolled only high risk patients such as diabetes mellitus or long lesions. He also mentioned that his study was not designed to evaluate the post-treatment platelet reactivity [24]. Similarly, Jeon's study conducted in 2010 demonstrated that there was no significant difference in the prevention of stent thrombosis between TAPT and DAPT groups but however, his study had a mixture of low and high risk patients [25]. Moreover, results from the HOST-ASSURE trial published in 2013 showed that the outcomes of both DAPT and TAPT were almost the same. TAPT was non inferior to double dose clopidogrel DAPT. However, the short follow-up period of 1 month could be a reason for this completely different result [26].

Other anti-platelet agents

Apart from this cilostazol based TAPT, there are other anti-platelet agents which can be used after intracoronary stenting. For example, the early use of glycoprotein IIb/IIIa inhibitors can reduce the occurrence of death or myocardial infarction in patients with acute coronary





Fig. 4 Forest plot comparing the adverse drug reactions between TAPT and DAPT in T2DM patients after intracoronary stenting. More adverse effects are associated with cilostazol use in this TAPT compared to DAPT in these T2DM patients

Bundhun et al. BMC Cardiovascular Disorders (2015) 15:118



clinical end points

syndromes who are not routinely scheduled for early revascularization. The event reduction is clinically most meaningful in patients at high risk of intracoronary thrombotic complications [27]. However, this drug can only be used for the short term in-hospital follow up. Moreover, the study by Geeganage's showed that TAPT based on i.v GPIIb/IIIa inhibitors was associated with a higher bleeding complication than that of the standard DAPT; however, the diabetic status of these patients was unknown [28].

New drugs such as prasugrel and ticagrelor are gradually becoming known among the antiplatelet agents. However, these drugs are associated with a higher bleeding tendency and they lack the anti-restenosis property which is only possible with the use of cilostazol and hence, rendering this cilostazol based TAPT to be a better option for T2DM patients.

Other potential benefits of cilostazol

Apart from being a part of TAPT, cilostazol alone has other potential indications. Studies have shown that cilostazol could reduce the symptoms of intermittent claudication [29, 30]. Cilostazol could also be used for the prevention of stroke in patients with non-cardio-embolic stroke [31]. Surprisingly, cilostazol has also shown to be beneficial to the heart. It can: increase the heart rate in patients with bradycardia, preventing ventricular fibrillation in patients suffering from Brugada syndrome, benefit patients with third degree atrio-ventricular block and could possibly act as a cardio-protective drug in patients with heart failure [32].

Novelty in this study

Contrary to other studies, this meta-analysis has strictly been conducted on T2DM patients and has combined the adverse cardiovascular outcomes such as MACEs, TLR, TVR and stent thrombosis with platelet reactivity such as PRI and PRU; and has included all of them into one study. It can be said that TAPT could be a more promising drug therapy than the standard DAPT in T2DM patients after intracoronary stenting both in terms of effectiveness and safety.

Limitations

Few limitations were as follow: First of all, because of the short follow up period and due to the limited study number and population size, the power of the analysis might be restricted to some extent. One study had a follow up of up to 2 years but this could not be considered for comparison because other studies did not have such long follow up periods. Secondly, due to the small population size, the results of this study may be affected to an extent. Also, the availability of new anti-platelet therapies such as prasugrel and ticagrelor could render TAPT useless in clinical practice. Unfortunately another limitation which restricts the use of this TAPT is that cilostazol is associated with a few adverse drug reactions such as rashes (RR 2.67; P = 0.01); gastrointestinal troubles (RR 1.76; P = 0.18); thrombocytopenia (RR 0.33; P = 0.50), hepatic dysfunction (RR 0.72; P = 0.67); palpitation (RR 6.18; *P* = 0.09) and headache (RR 3.56; *P* = 0.11). However, despite most of these adverse drug reactions being statistically insignificant in our study, drug discontinuation was significantly higher in the triple group (RR 3.75; *P* < 0.00001).

Conclusion

Since MACEs have been significantly decreased in the triple group, TAPT appears to be more effective than DAPT in T2DM patients after intracoronary stenting. The insignificant differences in stent thrombosis, bleeding and most adverse drug reactions between these 2 groups result in TAPT to be almost as safe as DAPT in these diabetic patients.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

PKB was responsible for the conception and design, acquisition of data, analysis and interpretation of data, drafting the initial manuscript and revising it critically for important intellectual content. TQ was responsible for acquisition of data, interpretation of data and for revising the manuscript critically for important intellectual content. MHC was responsible for the conception and design, acquisition of data, interpretation of data, interpretation of data, and for revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

There was no external funding source for this research.

Received: 26 June 2015 Accepted: 25 September 2015 Published online: 09 October 2015

References

- De Luca G, Dirksen MT, Spaulding C, Kelbæk H, Schalij M, Thuesen L, et al. Impact of diabetes on long-term outcome after primary Angioplasty: insights from the DESERT cooperation. Diabetes Care. 2013;36(4):1020–5.
- Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26:2181–8.
- Geisler T, Anders N, Paterok M, Langer H, Stellos K, Lindemann S, et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007;30:372–4.
- Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA. 2013;310(2):189–98.
- Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (a randomized comparison of triple antiplatelet therapy with dual antiplatelet therapy after drug-eluting stent implantation in diabetic patients). J Am Coll Cardiol. 2008;51:1181–7.
- Han Y, Li Y, Wang S, Jing Q, Wang Z, Wang D, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary interve ntion in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J. 2009;157(4):733–9.
- Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation. 2000;102:624–9.
- Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
- Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430–5.
- 11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
- Savi P, Zachayus JL, Delesque-Touchard N, Labouret C, Herve C, Uzabiaga MF, et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A. 2006;103:11069–74.
- Sumpio BE, Aruny J. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. Perspect Vasc Surg Endovasc Ther. 2005;17:265–7.
- Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care. 2009;32(4):531–40.
- Mohammad RA, Goldberg T, Dorsch MP, Cheng JW. Antiplatelet therapy after placement of a drug-eluting stent: a review of efficacy and safety studies. Clin Ther. 2010;32(14):2265–81.
- Bangalore S, Singh A, Toklu B, DiNicolantonio JJ, Croce K, Feit F, et al. Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart. 2014;1(1), e000068.

- Min P-K, Jung J, Ko YG, Choi D, Jang Y, Shim WH. Effect of cilostazol on in-stent neointimal hyperplasia after coronary artery stenting. Circ J. 2007;71:1685–90.
- Lee S-W, Park S, Yun S, Kim YH, Park DW, Kim WJ, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-eluting stenting followed by cilostazol treatment reduces adverse serious cardiac events (DECREASE registry). Am Heart J. 2010;284–91.
- Sakurai R, Koo BK, Kaneda H, Bonneau HN, Nagai R. Cilostazol added to aspirin and clopidogrel reduces revascularization without increases in major adverse events in patients with drug-eluting stents: a meta-analysis of randomized controlled trials. Int J Cardiol. 2013;167:2250–8.
- Kim IS, Jeong YH, Park Y, Park KS, Yun SE, Park JR, et al. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. JACC Cardiovasc Interv. 2011;4:381–91.
- Douglas Jr JS, Holmes Jr DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation. 2005;112(18):2826–32.
- Jeong YH, Hwang JY, Kim IS, Park Y, Hwang SJ, Lee SW, et al. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance doseclopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus highmaintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Circ Cardiovasc Interv. 2010;3(1):17–26.
- Ahn Y, Jeong MH, Jeong JW, Kim KH, Ahn TH, Kang WC, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients–clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J. 2008;72(1):35–9.
- 24. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease results of the CILON-T (Influence of CILostazolbased triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) Trial. J Am Coll Cardiol. 2011;57:280–9.
- Doo-Soo Jeon MD, Yoo K-D, Park CS, Shin DI, Her SH, et al. The effect of cilostazol on stent thrombosis after drug-eluting stent implantation. Korean Circ J. 2010;40(1):10–5.
- 26. Rogers KC, Faircloth JM, Finks SW. Use of cilostazol in percutaneous coronary interventions. Ann Pharmacother. 2012;46:839–50.
- Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al. Platelet glycoprotein Ilb/Illa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189–98.
- Geeganage C, Wilcox R, Bath PMW. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med. 2010;8:36.
- Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001;87(12A):28D–33.
- Rendell M, Cariski AT, Hittel N, Zhang P. Cilostazol treatment of claudication in diabetic patients. Curr Med Res Opin. 2002;18(8):479–87.
- Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirincontrolled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010;9(10):959–68. doi:10.1016/S1474-4422(10)70198-8.
- Kanlop N, Chattipakorn S, Chattipakorn N. Effects of cilostazol in the heart. J Cardiovasc Med (Hagerstown). 2011;12(2):88–95.
- 33. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelettherapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol. 2011;57(11):1264–70.
- Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am J Cardiol. 2007;100(7):1103–8.
- Yang TH, Kim DI, Kim DK, Jang JS, Kim U, Seol SH, et al. Detection of clopidogrel hyporesponsiveness using a point-of-care assay and the impact of additional cilostazol administration after coronary stent implantation in diabetic patients. Korean J Intern Med. 2011;26(2):145–52.

- Yang TH, Kim DI, Kim JY, Kim IH, Kim KH, Han YC, et al. Comparison of triple anti-platelet therapy (aspirin, clopidogrel, and cilostazol) and double anti-platelet therapy (aspirin and clopidogrel) on platelet aggregation in type 2 diabetic patients undergoing drug-eluting stent implantation. Korean Circ J. 2009;39(11):462–6.
- 37. Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, Darlington A, et al. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheter Cardiovasc Interv. 2013;81(1):42–9.
- Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008;29:2202–11.
- Angiolillo DJ, Capranzano P, Ferreiro JL, Ueno M, Capodanno D, Dharmashankar K, et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost. 2011;106(2):253–62.
- Ha SJ, Kim SJ, Hwang SJ, Woo JS, Kim W, Kim WS, et al. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. Coron Artery Dis. 2013;24(8):690–7.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

) BioMed Central

Submit your manuscript at www.biomedcentral.com/submit